Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Arguedas

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Endoscopy|February 7, 2004
Suspected sphincter of Oddi dysfunction type II: empirical biliary sphincterotomy or manometry-guided therapy?M R Arguedas, J D Linder, C M Wilcox
Alimentary Pharmacology & Therapeutics|May 1, 2001
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysisM R Arguedas, G R Heudebert, C M Wilcox
Alimentary Pharmacology & Therapeutics|February 28, 2004
Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleedingD L Raines, A W Dupont, M R Arguedas
The American Journal of Gastroenterology|November 6, 2001
Where do ERCP, endoscopic ultrasound, magnetic resonance cholangiopancreatography, and intraoperative cholangiography fit in the management of acute biliary pancreatitis? A decision analysis modelM R Arguedas, A W Dupont, C M Wilcox
Alimentary Pharmacology & Therapeutics|April 4, 2002
Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?B F Thompson, M R Arguedas, C M Wilcox
Digestive Diseases and Sciences|May 14, 2004
Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver diseaseC D Wells, W B Murrill, M R Arguedas
Alimentary Pharmacology & Therapeutics|July 20, 2007
Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysisA W DuPont, M R Arguedas, C M Wilcox
Hepatology (Baltimore, Md.)|June 30, 2001
Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patientsM R Arguedas, A Johnson, M A Eloubeidi, et al.
The American Journal of Gastroenterology|March 31, 2001
The use of screening and preventive therapies for gastroesophageal varices in patients referred for evaluation of orthotopic liver transplantationM R Arguedas, B M McGuire, M B Fallon, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2002
Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical studyB L Hicken, A I Sharara, G A Abrams, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Endoscopy|February 7, 2004
Suspected sphincter of Oddi dysfunction type II: empirical biliary sphincterotomy or manometry-guided therapy?M R Arguedas, J D Linder, C M Wilcox
Alimentary Pharmacology & Therapeutics|May 1, 2001
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysisM R Arguedas, G R Heudebert, C M Wilcox
Alimentary Pharmacology & Therapeutics|February 28, 2004
Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleedingD L Raines, A W Dupont, M R Arguedas
The American Journal of Gastroenterology|November 6, 2001
Where do ERCP, endoscopic ultrasound, magnetic resonance cholangiopancreatography, and intraoperative cholangiography fit in the management of acute biliary pancreatitis? A decision analysis modelM R Arguedas, A W Dupont, C M Wilcox
Alimentary Pharmacology & Therapeutics|April 4, 2002
Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?B F Thompson, M R Arguedas, C M Wilcox
Digestive Diseases and Sciences|May 14, 2004
Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver diseaseC D Wells, W B Murrill, M R Arguedas
Alimentary Pharmacology & Therapeutics|July 20, 2007
Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysisA W DuPont, M R Arguedas, C M Wilcox
Hepatology (Baltimore, Md.)|June 30, 2001
Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patientsM R Arguedas, A Johnson, M A Eloubeidi, et al.
The American Journal of Gastroenterology|March 31, 2001
The use of screening and preventive therapies for gastroesophageal varices in patients referred for evaluation of orthotopic liver transplantationM R Arguedas, B M McGuire, M B Fallon, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2002
Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical studyB L Hicken, A I Sharara, G A Abrams, et al.
Pageof 2